Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What makes MUC1 a tumor antigen?

Uwe Karsten1, Silvia von Mensdorff-Pouilly, Steffen Goletz

  • 1Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany. uwe.karsten@glycotope.com

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|July 12, 2005
PubMed
Summary

Tumor cells alter epithelial mucin 1 (MUC1) glycosylation. Understanding these changes is key for developing effective MUC1 cancer vaccines and antibody therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics analysis reveals dermokine as a regulator of keratinocyte differentiation and adhesion.

JCI insight·2026
Same author

The Role of Glycan Structures in Modulating GM-CSF Bioactivity: Insights from Glycoengineering.

bioRxiv : the preprint server for biology·2026
Same author

<i>MGAT1</i> knockout in human dendritic cells enhance CD8<sup>+</sup> T cell activation.

Frontiers in immunology·2026
Same author

Meta-inflammation and endotoxemia in a highly translational porcine model of diet-induced obesity.

Lab animal·2025
Same author

Implications of glycosylation for the development of selected cytokines and their derivatives for medical use.

Biotechnology advances·2024
Same author

Chemical synthesis and immunological evaluation of cancer vaccines based on ganglioside antigens and α-galactosylceramide.

RSC medicinal chemistry·2024

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Epithelial mucin 1 (MUC1) is a well-established serum tumor marker and cellular tumor antigen.
  • Aberrant glycosylation of MUC1 is a hallmark of many cancers, distinguishing tumor-associated MUC1 from its normal counterpart.

Purpose of the Study:

  • To review current understanding of the differences between normal and tumor-associated MUC1.
  • To explore the implications of these MUC1 alterations for cancer vaccine and antibody therapy development.

Main Methods:

  • Literature review of recent research on MUC1 structure, function, and glycosylation.
  • Analysis of studies investigating MUC1 as a target for cancer immunotherapy.

Main Results:

  • Tumor-specific MUC1 exhibits distinct glycoforms compared to normal MUC1.
  • These glycosylation differences present unique antigenic targets for therapeutic intervention.

Conclusions:

  • Targeting tumor-associated MUC1 glycosylation holds significant promise for developing novel cancer vaccines and antibody-based therapies.
  • Further research into MUC1 glycosylation is crucial for optimizing immunotherapeutic strategies.

Related Experiment Videos